Combined with previous studies, data suggest that the introduction of HAART therapy and second generation protease inhibitors allowed substantially decreased burden of infections by opportunistic pathogens affecting the patients in the earlier stages of the disease, probably because the treatment causes increase in CD4+ cell counts and thus improves the host defense. Here, CD4 is linked to infection.